¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ±â¼úº°, °³¹ß ´Ü°èº°, Ä¡·á Á¾·ùº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Gene Editing Therapeutics Market, By Technology, By Development Stage, By Therapy Type, By Disease Indication, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1756395
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 260 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,449,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,366,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,735,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â 1,113¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2025³âºÎÅÍ 2032³â±îÁö CAGR 147.20%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ

ȹ±âÀûÀÎ ÀÓ»ó ½ÂÀΰú Á¤¹ÐÇÑ µµ±¸·Î Ä¡·áÁ¦ äÅà ÃËÁø

Vertex Pharmaceuticals¿Í CRISPR Therapeutics°¡ Á¦ÈÞÇÏ¿© °³¹ßÇÑ °â»ó ÀûÇ÷±¸Áõ¿¡ ´ëÇÑ Ã¹ ¹øÂ° CRISPR ±â¹Ý Ä¡·áÁ¦°¡ ¹Ì±¹ FDAÀÇ ½ÂÀÎÀ» ¹ÞÀ½À¸·Î½á Àü ¼¼°èÀûÀ¸·Î À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. 2023³â ½ÂÀÎÀº À¯ÀüÀÚ ÆíÁýÀÇ ÀÓ»ó Àû¿ëÀ» ÇâÇÑ ¿ª»çÀûÀÎ ÀüȯÁ¡ÀÌ µÇ¾ú½À´Ï´Ù. µ¿½Ã¿¡ ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)Àº Á¤¹Ð À¯Àüü °øÇÐ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀ» ´Ã¸®°í, Ç¥Àû ¿Ü ¿µÇâÀÌ ÀûÀº µ¹¿¬º¯À̸¦ ±³Á¤Çϱâ À§ÇÑ ¿°±â±³Á¤ ¹× ÇÁ¶óÀÓ ÆíÁý°ú °°Àº µµ±¸¸¦ Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¿µ±¹¿¡¼­´Â ÀǾàǰ ¹× ÇコÄɾî Á¦Ç° ±ÔÁ¦Ã»(MHRA)ÀÌ À¯ÀüÀÚ ÆíÁý Ä¡·áÀÇ Á¶±â ½É»ç °æ·Î¸¦ °³½ÃÇÏ¿© ÷´Ü Ä¡·á¹ýÀ» ȯÀÚ¿¡°Ô ´õ »¡¸® Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº À¯ÀüÀÚ ÆíÁýÀÇ ¾ÈÀüÇϰí È¿À²ÀûÀ̸ç È®Àå °¡´ÉÇÑ Ä¡·áÀû ÀÀ¿ë¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½ÉÀÇ Áõ°¡¸¦ ¹Ý¿µÇϰí ÀÖÀ¸¸ç, À¯Àü¼º Áúȯ, ¾Ï ¹× º¹ÀâÇÑ ÁúȯÀÇ Ä¡·á¸¦ º¯È­½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¿¬±¸ ºÐ¼®°¡µéÀÌ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 147.20%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â¼úº°·Î´Â CRISPRÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.

°³¹ß ´Ü°èº°·Î´Â 2024³â ÀüÀÓ»óÀÌ 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.

Ä¡·á À¯Çüº°·Î´Â ü¿Ü À¯ÀüÀÚ ÆíÁýÀÌ 2024³â ÁÖ¿ä Ä¡·á À¯ÇüÀ¸·Î ²ÅÇû½À´Ï´Ù.

ÀûÀÀÁõº°·Î´Â À¯ÀüÀÚ ÁúȯÀÌ 2024³â ÁÖ¿ä ÁúȯÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â ¹ÙÀÌ¿À Á¦¾àȸ»ç°¡ 2024³â ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°è À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀåÀº ±â¼ú, °³¹ß ´Ü°è, Ä¡·á À¯Çü, Á¦¿Õ¼º, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ±â¼ú¿¡ µû¶ó CRISPR, ZFN, TALEN, ¿°±â±³Á¤, RNA ÆíÁý, CRISPRÀÌ °£Æí¼º°ú °íÈ¿À²·Î ¼±µÎ¸¦ ´Þ¸®°í ÀÖ°í, ZFNÀº ƯÀ̼ºÀ» Á¦°øÇÏÁö¸¸ º¹ÀâÇÑ ¼³°è°¡ ÇÊ¿äÇϸç, TALENÀº À¯ÀüÀÚ ³ì¾Æ¿ô ¿¬±¸¿¡¼­ Ç¥Àû Á¤È®µµ·Î Æò°¡µÇ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ³ì¾Æ¿ô ¿¬±¸¿¡¼­ÀÇ Ç¥Àû Á¤È®µµ·Î Æò°¡µÇ°í ÀÖÀ¸¸ç, ¿°±â±³Á¤Àº ´ÜÀÏ ¿°±â º¯°æÀ» °¡´ÉÇÏ°Ô Çϰí, RNA ÆíÁýÀº DNA¸¦ º¯°æÇÏÁö ¾Ê°í ÀϽÃÀûÀÎ º¯ÇüÀÌ °¡´ÉÇÕ´Ï´Ù.

½ÃÀåÀº °³¹ß ´Ü°è¿¡ µû¶ó 5°¡Áö Ä«Å×°í¸®·Î ³ª´¹´Ï´Ù. ÀüÀÓ»ó, 1»ó, 2»ó, 3»ó, ½ÂÀÎ ÈÄÀÔ´Ï´Ù. ÀüÀÓ»ó ´Ü°è´Â ¸¹Àº ¼öÀÇ Èĺ¸¹°ÁúÀÌ Á¶»ç ÁßÀ̰í, ÀÓ»ó 1»óÀº ¾ÈÀü¼º ÇÁ·ÎÆÄÀϸµ¿¡ ÃÊÁ¡À» ¸ÂÃß°í, ÀÓ»ó 2»óÀº Ä¡·á È¿°ú¸¦ Á¶»çÇϸç, ÀÓ»ó 3»óÀº Àüü Áý´Ü¿¡ ´ëÇÑ ´ë±Ô¸ð °ËÁõÀ» Æ÷ÇÔÇÕ´Ï´Ù.

À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº° ºÐ¼®

À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀåÀº ÷´Ü »ý¸í°øÇÐ ÀÎÇÁ¶ó, ±¤¹üÀ§ÇÑ ÀÓ»ó ¿¬±¸ Ȱµ¿, FDA¿Í °°Àº ±â°üÀÇ Áö¿øÀûÀÎ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©·Î ÀÎÇØ ºÏ¹Ì¸¦ ÇʵηΠ°­·ÂÇÑ Áö¿ªÀû ¿ªµ¿¼ºÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¹Ì±¹Àº CRISPR ±â¹Ý Ä¡·á¹ýÀÇ ½ÂÀÎ ¹× ÀÓ»ó½ÃÇè¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, °ø°ø ¹× ¹Î°£À¸·ÎºÎÅÍÀÇ ¸·´ëÇÑ ÀÚ±Ý Áö¿øÀ¸·Î °­È­µÇ°í ÀÖ½À´Ï´Ù. ¿µ±¹, µ¶ÀÏ, ½ºÀ§½º µîÀÇ ±¹°¡µéÀÌ Á¤¹ÐÀÇ·á¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖÀ¸¸ç, EMA¿Í °°Àº ±ÔÁ¦ ±â°üµµ Çõ½ÅÀûÀÎ À¯ÀüÀÚ Ä¡·á¹ýÀ» Á¡Á¡ ´õ ¸¹ÀÌ ¼ö¿ëÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ƯÈ÷ Áß±¹°ú ÀϺ»¿¡¼­´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿Í »ý¸í°øÇÐ ±â¾÷°úÀÇ Á¦ÈÞ¸¦ ÅëÇØ À¯ÀüÀÚ ÆíÁý ¿¬±¸°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè°ú ±ÔÁ¦ °³Çõ¿¡ ´ëÇÑ Áß±¹ÀÇ Àû±ØÀûÀÎ Âü¿©´Â °æÀï ±¸µµ¸¦ Çü¼ºÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ¿ª·® ±¸Ãà°ú ¹Ì·¡ À¯ÀüÀÚ Ä¡·á ÅëÇÕÀ» À§ÇÑ ±ÔÁ¦ ¸ðµ¨ Àû¿ë¿¡ ÁßÁ¡À» µÎ¸é¼­ Çмú Á¦ÈÞ ¹× ÆÄÀÏ·µ ÇÁ·Î±×·¥À» ÅëÇØ Á¡Â÷ ÀÌ ºÐ¾ß¿¡ ÁøÀÔÇϰí ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : °æÀï »óȲ

À¯ÀüÀÚ±³Á¤ Ä¡·áÁ¦ ½ÃÀåÀÇ °æÀï ±¸µµ´Â »ý¸í°øÇÐ ±â¾÷, Á¦¾à ±â¾÷, ¾ÈÀüÇϰí È¿°úÀûÀÎ À¯ÀüÀÚ±³Á¤ Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ ³ë·ÂÇÏ´Â Çмú ¿¬±¸±â°üÀÌ È¥ÀçµÇ¾î Çü¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº CRISPR, TALEN, ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦(ZFN) ±â¹Ý Ä¡·áÁ¦¸¦ Àû±ØÀûÀ¸·Î °³¹ßÇϰí ÀÖÀ¸¸ç, ´Ù¾çÇÑ À¯Àü¼º Áúȯ°ú ¸¸¼ºÁúȯÀ» Ÿ°ÙÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷°ú ´ëÇü Á¦¾àȸ»ç¿ÍÀÇ Á¦ÈÞ´Â Àӻ󰳹߰ú ½ÂÀÎÀ» ¾Õ´ç±â±â À§ÇÑ ¸ñÀûÀ¸·Î Á¡Á¡ ´õ º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ ¸¸ÇÑ ÁøÀüÀ¸·Î´Â Ç÷¾× Áúȯ¿¡ ´ëÇÑ CRISPR ±â¹Ý Ä¡·á¹ý°ú ¾Ï¿¡ ´ëÇÑ CAR-T ¼¼Æ÷ °øÇÐ °øµ¿ °³¹ß Á¦ÈÞ µîÀÌ ÀÖ½À´Ï´Ù. Çмú ±â°üµµ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, Ãʱ⠴ܰèÀÇ ¿¬±¸¿Í µµ±¸ÀÇ °³¼±¿¡ ±â¿©ÇÏ°í ³ªÁß¿¡ Ä¡·á¿ëÀ¸·Î ¶óÀ̼¾½º¸¦ ºÎ¿©ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. µ¶Á¡ ¶óÀ̼±½º °è¾à, ±¹Á¦ ½ÃÀå ÁøÃâ, GMP Áؼö Á¦Á¶ ½Ã¼³¿¡ ´ëÇÑ ÅõÀÚ¿Í °°Àº Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ¸ÂÃãÇü Ä¡·á¿Í ±Ùº»ÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ÁßÁ¡À» µÎ°í °æÀï ¿ìÀ§¸¦ È®º¸ÇÏ´Â µ¥ ÀÖ¾î ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ »ê¾÷ Á¶»ç

Á¦5Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå »óȲ

Á¦7Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ±â¼úº°

Á¦8Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : °³¹ß ´Ü°èº°

Á¦9Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : Ä¡·á Á¾·ùº°

Á¦10Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ÀûÀÀÁõº°

Á¦11Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦12Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°

Á¦13Àå ÁÖ¿ä º¥´õ ºÐ¼® : À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ¾÷°è

Á¦14Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Gene Editing Therapeutics Market size was valued at US$ 11.13 Million in 2024, expanding at a CAGR of 147.20% from 2025 to 2032.

The Gene Editing Therapeutics Market centers on the development and commercialization of treatments that correct or modify genetic mutations at the DNA level to treat or potentially cure diseases. With increasing approvals for gene-editing therapies in rare and inherited disorders, the market is expanding into oncology and infectious diseases. In 2023, the U.S. FDA approved the first CRISPR-based therapy for sickle cell anemia, marking a major milestone in clinical gene editing. Technological innovations like base editing and prime editing are enhancing precision while minimizing off-target effects, making gene-editing tools safer for therapeutic use. However, high treatment costs, ethical concerns, and complex regulatory pathways continue to pose significant challenges to widespread adoption. Opportunities exist in the development of personalized medicine, targeting previously untreatable conditions, and expanding gene editing to common diseases, supported by increasing research funding from national health agencies and global biotech collaborations.

Gene Editing Therapeutics Market- Market Dynamics

Breakthrough clinical approvals and precision tools to boost therapeutic adoption

Breakthrough clinical approvals and precision tools are significantly boosting the adoption of gene editing therapeutics worldwide. The U.S. FDA's 2023 approval of the first CRISPR-based therapy for sickle cell disease, developed in partnership with Vertex Pharmaceuticals and CRISPR Therapeutics, marked a historic shift toward clinical application of gene editing. Simultaneously, the National Institutes of Health (NIH) has increased funding for precision genome engineering research, promoting tools like base editing and prime editing to correct mutations with fewer off-target effects. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has initiated accelerated review pathways for gene-editing therapies, aiming to bring advanced treatments to patients faster. These developments reflect a growing global emphasis on safe, efficient, and scalable therapeutic applications of gene editing, reinforcing its potential to transform the treatment of inherited disorders, cancers, and complex diseases.

Gene Editing Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 147.20% over the forecast period (2025-2032)

Based on Technology segmentation, CRISPR was predicted to show maximum market share in the year 2024

Based on Development Stage segmentation, Preclinical was the leading Development Stage in 2024

Based on Therapy Type segmentation, Ex Vivo Gene Editing was the leading Therapy Type in 2024

Based on Disease Indication segmentation, Genetic Disorders were the leading Disease Indication in 2024

Based on end user segmentation, Biopharma Companies was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Gene Editing Therapeutics Market- Segmentation Analysis:

The Global Gene Editing Therapeutics Market is segmented on the basis of Technology, Development Stage, Therapy Type, Disease Indication, End User, and Region.

The market is divided into five categories based on Technology: CRISPR, ZFN, TALEN, Base Editing, and RNA Editing. CRISPR leads due to its simplicity and high efficiency; ZFN offers specificity but requires complex design; TALEN is valued for targeting precision in gene knockout studies; base editing enables single-nucleotide changes; RNA editing allows transient modifications without altering DNA.

The market is divided into five categories based on Development Stage: Preclinical, Phase I, Phase II, Phase III, and Approved. Preclinical dominates with numerous candidates under investigation; Phase I focuses on safety profiling; Phase II explores therapeutic efficacy; Phase III involves large-scale validation across populations; Approved therapies mark successful transition from research to regulated treatment, gaining traction in rare genetic disorders.

Gene Editing Therapeutics Market- Geographical Insights

The Gene Editing Therapeutics Market exhibits strong regional dynamics, with North America at the forefront due to advanced biotech infrastructure, extensive clinical research activity, and supportive regulatory frameworks from agencies like the FDA. The U.S. leads in approvals and trials for CRISPR-based therapies, reinforced by substantial public and private funding. Europe follows closely, where countries such as the UK, Germany, and Switzerland are actively investing in precision medicine, and regulatory bodies like the EMA are increasingly receptive to innovative genetic treatments. The Asia-Pacific region is gaining traction, particularly in China and Japan, where government initiatives and biotech collaborations are accelerating gene editing research. China's active involvement in clinical trials and regulatory reforms is helping shape a competitive landscape. Latin America and the Middle East & and Africa are gradually entering the space through academic partnerships and pilot programs, focusing on capacity building and adapting regulatory models for future gene therapy integration.

Gene Editing Therapeutics Market- Competitive Landscape:

The competitive landscape of the Gene Editing Therapeutics Market is shaped by a mix of biotechnology firms, pharmaceutical companies, and academic research institutions striving to advance safe and effective gene-editing therapies. Leading players are actively developing CRISPR, TALEN, and zinc finger nuclease (ZFN)-based treatments, targeting a wide range of genetic and chronic diseases. Collaborations between biotech startups and large pharmaceutical companies are increasingly common, aimed at accelerating clinical development and regulatory approval. Notable advancements include partnerships to co-develop CRISPR-based therapies for blood disorders and CAR-T cell engineering for cancer. Academic institutions also play a vital role, contributing to early-stage research and tool refinement, which are later licensed for therapeutic use. Strategic initiatives such as exclusive licensing agreements, expansion into international markets, and investment in GMP-compliant manufacturing facilities are becoming central to gaining a competitive advantage, with a strong focus on developing personalized and curative therapies.

Recent Developments:

In May 2025, CRISPR Therapeutics and Sirius Therapeutics have announced a multi-target collaboration to develop novel siRNA therapies, including SRSD107 for thromboembolic disorders, aiming for best-in-class, long-acting gene-based treatments with infrequent dosing and improved patient outcomes.

In May 2025, NIH-supported researchers delivered the first personalized CRISPR gene-editing therapy to an infant with CPS1 deficiency. Using a rapid, customizable platform, the treatment corrected the genetic defect in liver cells within six months, marking a breakthrough for rare disease therapeutics.

In November 2023, Vertex and CRISPR Therapeutics received authorization for the world's first CRISPR-based gene editing therapy for sickle cell disease and beta thalassemia, marking a historic milestone in gene editing therapeutics and offering new hope for patients with these genetic disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENE EDITING THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Gene Editing Therapeutics Market Overview

2. Executive Summary

3. Gene Editing Therapeutics Key Market Trends

4. Gene Editing Therapeutics Industry Study

5. Gene Editing Therapeutics Market: Impact of Escalating Geopolitical Tensions

6. Gene Editing Therapeutics Market Landscape

7. Gene Editing Therapeutics Market - By Technology

8. Gene Editing Therapeutics Market - By Development Stage

9. Gene Editing Therapeutics Market - By Therapy Type

10. Gene Editing Therapeutics Market - By Disease Indication

11. Gene Editing Therapeutics Market - By End User

12. Gene Editing Therapeutics Market- By Geography

13. Key Vendor Analysis- Gene Editing Therapeutics Industry

14. 360 Degree Analyst View

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â